EQS-News: M1 Kliniken AG / Key word(s): Investment Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard 05.02.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. The two members of the Management Board of M1 Kliniken AG, Mr Attila Strauss and Mr Kilian Brenske, acquired a total of 1.5 million shares in the company from MPH Health Care AG on 2 February 2024. The Co-CEOs justify the share purchase with their confidence in the long-term growth prospects of M1 Kliniken AG and the desire to participate even more strongly in the strategic direction and development of the company.
Co-CEO Kilian Brenske explains: “We are firmly convinced that our investment will further strengthen investor confidence. The profitable growth of our group of companies remains the focus of our actions.” Co-CEO, Attila Strauss, adds: “Intensifying communication with external investors, a shareholder-friendly dividend policy and also a possible uplisting to the Prime Standard will be further focal points.” About M1 Kliniken AG: M1 Kliniken AG is the leading fully integrated provider of aesthetic medical health services in Europe. In the aesthetic and surgical fields, the group offers products and services with the highest quality standards. Currently, under the brand “M1 Med Beauty,” beauty medical treatments are offered at 59 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating rooms and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving internationalisation and is currently present in ten countries. 05.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Marijuana’s psychoactive compound may alter brain wiring in adolescents
In a mouse study designed to explore the impact of marijuana’s major psychoactive compound, THC, on teenage brains, Johns Hopkins Medicine researchers say they found